110 related articles for article (PubMed ID: 8549303)
21. Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones.
Nishijima S; Nakagawa M; Tsuboi N; Akamatsu H; Horio T; Fujita M; Kawabata S
J Int Med Res; 1996; 24(1):12-6. PubMed ID: 8674789
[TBL] [Abstract][Full Text] [Related]
22. Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
Reddy AK; Garg P; Alam MR; Gopinathan U; Sharma S; Krishnaiah S
Eye (Lond); 2010 Jan; 24(1):170-4. PubMed ID: 19229279
[TBL] [Abstract][Full Text] [Related]
23. In vitro pharmacodynamics of ofloxacin and ciprofloxacin against common ocular pathogens.
Eiferman RA
Cornea; 2001 May; 20(4):438-9. PubMed ID: 11333340
[No Abstract] [Full Text] [Related]
24. Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin, and other selected antimicrobial agents against Brucella melitensis.
Khan MY; Dizon M; Kiel FW
Antimicrob Agents Chemother; 1989 Aug; 33(8):1409-10. PubMed ID: 2802568
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of rufloxacin against Listeria monocytogenes, Legionella pneumophila, and Chlamydia trachomatis.
Furneri PM; Bazzano M; Campo L; Cesana M; Tempera G
Chemotherapy; 1994; 40(2):104-8. PubMed ID: 8131632
[TBL] [Abstract][Full Text] [Related]
26. Overview of the fluoroquinolone antibiotics.
Just PM
Pharmacotherapy; 1993; 13(2 Pt 2):4S-17S. PubMed ID: 8386356
[TBL] [Abstract][Full Text] [Related]
27. Decreased susceptibility of Neisseria gonorrhoeae to fluoroquinolones--Ohio and Hawaii, 1992-1994.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1994 May; 43(18):325-7. PubMed ID: 8164636
[TBL] [Abstract][Full Text] [Related]
28. From the Centers for Disease Control and Prevention. Decreased susceptibility of Neisseria gonorrhoeae to fluoroquinolones--Ohio and Hawaii, 1992-1994.
JAMA; 1994 Jun; 271(22):1733-4. PubMed ID: 8196105
[No Abstract] [Full Text] [Related]
29. Will pneumococci put quinolones in their place?
Legg JM; Bint AJ
J Antimicrob Chemother; 1999 Oct; 44(4):425-7. PubMed ID: 10588301
[No Abstract] [Full Text] [Related]
30. In vitro comparison of ciprofloxacin, ofloxacin, and povidone-iodine for surgical prophylaxis.
Keverline MR; Kowalski RP; Dhaliwal DK
J Cataract Refract Surg; 2002 Jun; 28(6):915-6. PubMed ID: 12036617
[No Abstract] [Full Text] [Related]
31. [Trends of fluoroquinolone-resistant strains isolated from clinical materials].
Konno M; Ohonari S; Itoh N; Ubukata K; Hashimoto Y; Kawakami S
Kansenshogaku Zasshi; 1988 Jul; 62(7):641-51. PubMed ID: 3141525
[No Abstract] [Full Text] [Related]
32. Changes in susceptibility to ciprofloxacin in a community in northern Israel.
Cahana Z; Gilboa A; Raz R
Drugs; 1995; 49 Suppl 2():173-4. PubMed ID: 8549292
[No Abstract] [Full Text] [Related]
33. Bacteriology of chronic otitis media, chronic sinusitis, and paranasal mucopyocele in Japan.
Ito K; Ito Y; Mizuta K; Ogawa H; Suzuki T; Miyata H; Kato N; Watanabe K; Ueno K
Clin Infect Dis; 1995 Jun; 20 Suppl 2():S214-9. PubMed ID: 7548557
[TBL] [Abstract][Full Text] [Related]
34. Emergence of resistance to fluoroquinolones among bacteria causing infections in food animals in Denmark.
Aarestrup FM; Jensen NE; Jorsal SE; Nielsen TK
Vet Rec; 2000 Jan; 146(3):76-8. PubMed ID: 10674696
[No Abstract] [Full Text] [Related]
35. Lomefloxacin disc susceptibility criteria--a reappraisal.
Smith JM; Hashmi ZS
J Antimicrob Chemother; 1990 Jul; 26(1):152-3. PubMed ID: 2211438
[No Abstract] [Full Text] [Related]
36. Short-term quinolones for successful eradication of multiply resistant Vibrio cholerae in adult patients.
Doğanci L; Gün H; Baysallar M; Albay A; Cinar E; Haznedaroğlu T
Scand J Infect Dis; 1995; 27(4):425-6. PubMed ID: 8658086
[TBL] [Abstract][Full Text] [Related]
37. In vitro susceptibility of anaerobic bacteria to temafloxacin.
Southern PM; Patel S
Clin Infect Dis; 1993 Jun; 16 Suppl 4():S334. PubMed ID: 8391861
[No Abstract] [Full Text] [Related]
38. Effectiveness and safety of ofloxacin in chronic otitis media and chronic sinusitis in adult outpatients.
Gehanno P; Cohen B
Eur Arch Otorhinolaryngol; 1993; 250 Suppl 1():S13-4. PubMed ID: 8476579
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of ciprofloxacin as a representative of veterinary fluoroquinolones in susceptibility testing.
Riddle C; Lemons CL; Papich MG; Altier C
J Clin Microbiol; 2000 Apr; 38(4):1636-7. PubMed ID: 10747156
[TBL] [Abstract][Full Text] [Related]
40. Susceptibility of bacterial isolates from complicated skin and skin structure infections to cefazolin, imipenem-cilastatin, ciprofloxacin and ofloxacin.
Liu HH; Bolash NK; McAnany ME; Lynch RA
Drugs; 1995; 49 Suppl 2():215-8. PubMed ID: 8549308
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
